July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of …
Cleansing Statement
Appendix 3B
Proposed Issue of Securities
Corporate Governance Statement and is accessible at the Corporate Governance Page.
22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma …
Response to ASX Appendix 4C Query
Appendix 4C – Quarterly report for entities subjected to Listing Rule 4.7B: Download here.
Appendix 4D – Half Yearly Report and Accounts
February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged …